by demonstrating “a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.

The debate about the effectiveness of phenylephrine as an oral decongestant has been going on for some time and science now ...

The US Food and Drug Administration announced a proposal to remove oral phenylephrine - a common ingredient in many popular ...

A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...

Only a final order will affect what products can be marketed. Among the products containing oral phenylephrine as an active ingredient are Sudafed PE, Vicks Nyquil Sinex Nighttime Sinus Relief and ...

Share on Facebook Share on Twitter The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the ...